More great news the generic medication front. One of the key classes of medications we use in the treatment of hypertension, heart failure, and diabetes are the Angiotensin 2 Receptor Blockers (ARBs). The first drug to market in this class was losartin, marketed as Cozaar by Merck. Teva Pharmaceuticals, one of the largest generic drug companies, was granted FDA approval this week to sell generic losartin (see losartin side effects) in all of the same doses as Cozaar, and as a combination drug with hydrochlorothiazide like Hyzaar. In the treatment of hypertension the ARBs have been one of the last key drug classes without an inexpensive generic option until now. This will be great for our seniors on fixed incomes, and for keeping the drug costs of chronic disease management down. One of the key uses of the ARBs is in patients with cough as an adverse effect of an Angiotensin Converting Enzyme Inhibitor.
Medpage today has a good article on this news:
|FDA Approves First Generic ARBs|
More good news is that the patent for Avapro, an even more popular ARB than Cozaar, expires in 2010 also.